Weill Cornell Medicine
1300 York Ave
10 articles with Weill Cornell Medicine
The Leukemia & Lymphoma Society Launches IMPACT Research Grants to Help Underserved Patients Access Clinical Trials
Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical Trials
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
Researchers at Weill Cornell Medicine identified a specific and unique kind of immune cell activity in the lungs of COVID-19 patients.
Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis
Weill Cornell Medicine's Dr. Richard Granstein, M.D., Chairman of Dermatology, will collaborate with Biohaven to study a Calcitonin Gene-Related Peptide (CGRP) receptor-antagonist in plaque psoriasis
CareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMapUroMap Gene Expression Test Will Add to CareDx’s Best In Class Transplant Surveillance Comprehensive Solutions
CareDx, Inc. announced a strategic alliance with Weill Cornell Medicine that makes CareDx the exclusive development and commercialization partner of UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.
Study Identifies the Molecular Mechanisms by which Noonan Syndrome RAF1 mutations cause Cardiac Hypertrophy
Investigators from the Masonic Medical Research Institute, Weill Cornell Medicine and Beth Israel Deaconess Medical Center have identified the molecular mechanisms by which RAF1 mutations in patients with Noonan Syndrome cause hypertrophic cardiomyopathy, a dangerous thickening of the heart muscle that can lead to heart failure and death.
Consuming the equivalent of one can of soda per day caused mice predisposed to colon cancer to develop larger tumors, according to a study by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Gotham Therapeutics launched in New York with a $54 million Series A financing. The focus is on a subgroup of RNA metabolism called epitranscriptomics. This involves the biochemical modifications of RNA within a cell, which have an impact on gene expression.
July 13 Research Roundup: Gene Therapy for Cholesterol, Beta-Thalassemia, and Kidney Disease, and...
7/13/2018There are plenty of great scientific research stories out this week. Here’s a look at just a few of them from gene therapy for cholesterol to kidney disease and more.
TriNetX is a network comprised of healthcare organizations representing nearly 100 million patients globally, biopharmaceutical companies, and CROs.